Jatrorrhizine hydrochloride exhibits neuroprotective, antibacterial, antimalarial, and antioxidant activities; it is a potent and orally active acetylcholinesterase (AChE) inhibitor (IC50 = 872 nM) with 115-fold selectivity over butyrylcholinesterase (BuChE); it reduces serotonin (5-HT) and norepinephrine (NE) reuptake by inhibiting uptake-2 transporters, including hOCT2, hOCT3, and PMAT; it demonstrates antiplasmodial activity against Plasmodium falciparum (IC50 = 3.15 µM) and antiamoebic activity against Entamoeba histolytica (IC50 = 82.7 µM); it shows potential antidepressant-like effects in vivo, significantly reducing immobility time in the tail suspension test (TST) in mice at doses of 5, 10, and 20 mg/kg (i.p.).